These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31451509)

  • 21. Oxysterol-binding protein-related protein (ORP) 6 localizes to the ER and ER-plasma membrane contact sites and is involved in the turnover of PI4P in cerebellar granule neurons.
    Mochizuki S; Miki H; Zhou R; Kido Y; Nishimura W; Kikuchi M; Noda Y
    Exp Cell Res; 2018 Sep; 370(2):601-612. PubMed ID: 30028970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
    Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
    Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Membrane curvature sensing of the lipid-anchored K-Ras small GTPase.
    Liang H; Mu H; Jean-Francois F; Lakshman B; Sarkar-Banerjee S; Zhuang Y; Zeng Y; Gao W; Zaske AM; Nissley DV; Gorfe AA; Zhao W; Zhou Y
    Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31296567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission.
    van der Hoeven D; Cho KJ; Ma X; Chigurupati S; Parton RG; Hancock JF
    Mol Cell Biol; 2013 Jan; 33(2):237-51. PubMed ID: 23129805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong
    Rafael D; Montero S; Carcavilla P; Andrade F; German-Cortés J; Diaz-Riascos ZV; Seras-Franzoso J; Llaguno M; Fernández B; Pereira A; Duran-Lara EF; Schwartz S; Abasolo I
    ACS Appl Mater Interfaces; 2023 Mar; 15(8):10398-10413. PubMed ID: 36795046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactome map uncovers phosphatidylserine transport by oxysterol-binding proteins.
    Maeda K; Anand K; Chiapparino A; Kumar A; Poletto M; Kaksonen M; Gavin AC
    Nature; 2013 Sep; 501(7466):257-61. PubMed ID: 23934110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. INTRACELLULAR TRANSPORT. Phosphatidylserine transport by ORP/Osh proteins is driven by phosphatidylinositol 4-phosphate.
    Moser von Filseck J; Čopič A; Delfosse V; Vanni S; Jackson CL; Bourguet W; Drin G
    Science; 2015 Jul; 349(6246):432-6. PubMed ID: 26206936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycolysis regulates KRAS plasma membrane localization and function through defined glycosphingolipids.
    Liu J; van der Hoeven R; Kattan WE; Chang JT; Montufar-Solis D; Chen W; Wong M; Zhou Y; Lebrilla CB; Hancock JF
    Nat Commun; 2023 Jan; 14(1):465. PubMed ID: 36709325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS regulation by small non-coding RNAs and SNARE proteins.
    Che Y; Siprashvili Z; Kovalski JR; Jiang T; Wozniak G; Elcavage L; Khavari PA
    Nat Commun; 2019 Nov; 10(1):5118. PubMed ID: 31712554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
    Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Acid Sphingomyelinase Depletes Cellular Phosphatidylserine and Mislocalizes K-Ras from the Plasma Membrane.
    Cho KJ; van der Hoeven D; Zhou Y; Maekawa M; Ma X; Chen W; Fairn GD; Hancock JF
    Mol Cell Biol; 2016 Jan; 36(2):363-74. PubMed ID: 26572827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma membrane phosphatidylinositol 4-phosphate and 4,5-bisphosphate determine the distribution and function of K-Ras4B but not H-Ras proteins.
    Gulyás G; Radvánszki G; Matuska R; Balla A; Hunyady L; Balla T; Várnai P
    J Biol Chem; 2017 Nov; 292(46):18862-18877. PubMed ID: 28939768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors.
    Wang P; van der Hoeven D; Ye N; Chen H; Liu Z; Ma X; Montufar-Solis D; Rehl KM; Cho KJ; Thapa S; Chen W; van der Hoeven R; Frost JA; Hancock JF; Zhou J
    Eur J Med Chem; 2021 May; 217():113381. PubMed ID: 33756124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport.
    Schmick M; Vartak N; Papke B; Kovacevic M; Truxius DC; Rossmannek L; Bastiaens PIH
    Cell; 2014 Apr; 157(2):459-471. PubMed ID: 24725411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.
    Vicent S; Chen R; Sayles LC; Lin C; Walker RG; Gillespie AK; Subramanian A; Hinkle G; Yang X; Saif S; Root DE; Huff V; Hahn WC; Sweet-Cordero EA
    J Clin Invest; 2010 Nov; 120(11):3940-52. PubMed ID: 20972333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
    Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
    Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Both the PH domain and N-terminal region of oxysterol-binding protein related protein 8S are required for localization to PM-ER contact sites.
    Lee M; Fairn GD
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1088-1094. PubMed ID: 29409900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
    Nussinov R; Tsai CJ; Jang H
    Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.